UNITED KINGDOM —London-based artificial intelligence drug discovery firm Isomorphic Labs has closed a $5 billion Series C financing round. The investment was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued backing from Alphabet. Existing supporters, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund, also maintained their positions in this latest capital raise.
Isomorphic Labs is a computational biology enterprise spun out of DeepMind in 2021. Under the direction of CEO Sir Demis Hassabis, the organization specializes in applying advanced machine learning architectures to model complex biological systems and design novel therapeutic molecules. The newly acquired capital is designated to accelerate the expansion of its proprietary drug design engine, known as IsoDDE, and to propel its pipeline of AI-generated therapeutic candidates into human clinical trials.
This capital injection highlights a critical inflection point for the intersection of technology and pharmaceutical research. By transitioning AI-designed molecules from computational models into clinical validation, the company addresses a longstanding bottleneck in traditional drug development. The involvement of both prominent venture capital firms and sovereign wealth entities underscores an institutional consensus that machine learning is becoming a foundational pillar of modern biomedical research.
For investors and pharmaceutical stakeholders, this development signals a maturing market where AI-driven discovery platforms are demonstrating clear pathways to commercial viability. The substantial valuation implied by this round establishes a high barrier to entry for emerging competitors, effectively consolidating market leadership among well-capitalized pioneers. Consequently, traditional pharmaceutical companies may increasingly seek strategic partnerships with established AI biotech firms to secure access to next-generation therapeutic pipelines.